论文部分内容阅读
目的 :观察替格瑞洛应用于接受PCI介入治疗的不稳定型心绞痛患者的临床效果。方法 :将85于我院接受介入治疗的不稳定型心绞痛患者随机分为观察组和对照组。对照组给予氯吡格雷治疗,研究组给予替格瑞洛治疗。观察治疗随访至6个月。比较2组患者治疗前及治疗后12 h、7 d、1个月的C-反应蛋白(CRP)、白细胞介素-6(IL-6)、髓过氧物酶(MPO)的变化,术后半年时进行CAG及IVUS检查,了解患者支架内再狭窄的发生情况。比较2组患者的临床疗效以及不良反应的发生情况。结果 :观察组临床疗效显效、有效及无效比例分别是35、6、4例,好于对照组比例(24、6、10例)。观察患者的CRP、IL-6、MPO低于对照组,支架内再狭窄的发生率也低于对照组。两组患者药物的不良反应出血、呼吸困难未表现出明显的区别。结论 :与氯吡格雷相比,替格瑞洛具有更好的抑制炎症的效果,ISR的发生率也低。
Objective: To observe the clinical effect of ticagrelor in unstable angina patients undergoing PCI intervention. Methods: 85 patients with unstable angina who underwent interventional therapy in our hospital were randomly divided into observation group and control group. The control group was given clopidogrel and the study group was given ticagrelor. Follow-up observation to 6 months. The changes of C-reactive protein (CRP), interleukin-6 (IL-6) and myeloperoxidase (MPO) in two groups before treatment and 12 h, 7 d and 1 month after treatment were compared After the second half of CAG and IVUS examination to understand the occurrence of in-stent restenosis. The clinical efficacy and the incidence of adverse reactions in the two groups were compared. Results: The clinical efficacy of the observation group was significant, effective and ineffective ratio was 35,6,4 cases, better than the control group (24,6,10 cases). Observed in patients with CRP, IL-6, MPO lower than the control group, the incidence of stent restenosis was also lower than the control group. Two groups of patients with adverse drug reactions bleeding, dyspnea did not show a significant difference. CONCLUSION: Ticagrelor has a better anti-inflammatory effect than clopidogrel, and the incidence of ISR is also low.